Cite
HARVARD Citation
Quiroga, V. et al. (n.d.). 88PRun-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Annals of oncology. p. . [Online].